Core Insights - Akari Therapeutics has appointed Torsten Hombeck, Ph.D. as Chief Financial Officer effective December 16, 2024, bringing over 20 years of experience in biotechnology, finance, and M&A transactions [1][2][3] - Dr. Hombeck previously served as CFO of Akari from 2019 to June 2023, where he raised over $50 million, and has a strong background in clinical development and commercial expertise [3][4] - The company is focused on advancing its first-in-class antibody-drug conjugate (ADC) platform and believes there is significant potential to drive shareholder value [3][5] Company Overview - Akari Therapeutics is a biotechnology company developing therapies for autoimmune, oncology, and inflammatory diseases, with lead assets including investigational nomacopan and an ADC platform [5] - Nomacopan is a bispecific recombinant inhibitor targeting complement C5 activation and leukotriene B4 activity, currently undergoing pre-clinical research for geographic atrophy [5]
Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer